公开(公告)号：US20190184028A1

公开(公告)日：2019-06-20

申请号：US16218990

申请日：2018-12-13

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Andrew Elias ,  Shalom Goldberg ,  Donna Klein ,  Elise Kuhar ,  Tricia Lin ,  Lavanya Peddada ,  Karyn O'Neil ,  Kristen Wiley

IPC: A61K47/68 ,  A61P35/00 ,  C07K14/78 ,  A61P37/06 ,  B82Y5/00 ,  A61K47/69 ,  A61K47/64 ,  A61K47/42 ,  A61K31/7105

CPC classification number: A61K47/6807 ,  A61K31/7105 ,  A61K47/42 ,  A61K47/6415 ,  A61K47/6925 ,  A61K47/6929 ,  A61P35/00 ,  A61P37/06 ,  B82Y5/00 ,  C07K14/78

Abstract: A fibronectin type III (FN3) domain-nanoparticle or direct conjugate complex containing a polynucleotide molecule, a toxin, polynucleotide molecule or other pharmaceutically active payload is obtained by panning an FN3 domain library with a protein or nucleotide of interest, recovering the FN3 domain and conjugating the FN3 domain with a toxin or nanoparticle containing an active polynucleotide, such as an ASO or siRNA molecule. A fibronectin type III (FN3) domain-nucleic acid conjugate is obtained by panning an FN3 domain library with a protein or nucleotide of interest, recovering the FN3 domain and conjugating the FN3 domain to a nucleic acid (e.g., ASO or siRNA). The nanoparticle complex, nucleic acid conjugate or FN3 domain toxin conjugate may be used in the treatment of diseases and conditions, for example, oncology or auto-immune indications.